Telix International Pty Ltd

ZIRCON

NCT03849118

JCP092

A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

89Zr-girentuximab

PET/CT imaging

Treatment Arms

o Experimental: 89Zr-girentuximab